Clinical trial
SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe…
NCT00361959 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00361959 |
|---|---|
| Title | SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease |
| Official title | Multicentre, Randomised, Double-Blind, Double Dummy, Parallel Group, 104-week Study to Compare the Effect of the Salmeterol/Fluticasone Propionate Combination Product (SERETIDE*) 50/500mcg Delivered Twice Daily Via the DISKUS*/ACCUHALER* Inhaler With Tiotropium Bromide 18 mcg Delivered Once Daily… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Drug |
| Interventions | Tiotropium bromide 18mcg, Fluticasone propionate/ salmeterol combination 50/500mcg |
| Enrollment | 1,270 |
| Start date | Jun 1, 2003 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2006 |
| First posted | Aug 9, 2006 |
| Last update posted | Jan 20, 2017 |
| Countries | Austria, Belgium, Czechia, Denmark, Estonia, Germany, Greece, Italy, Latvia, Lithuania, Netherlands, Norway and 8 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: